Intrahepatic cholangiocarcinoma is in most transplant regions a contraindication for liver transplantation, even ruling out an active waiting list registration. However, recent studies showed that well-selected patients after a neo-adjuvant treatment benefit from liver transplantation with good long-term outcomes. The role of living donor liver transplantation is unclear for this indication. The current study focuses on LDLT for intrahepatic cholangiocarcinoma.
Background: Data about liver transplantation for mixed tumors from hepatocellular carcinoma to cholangiocarcinoma are limited. Furthermore, the diagnosis of intrahepatic cholangiocarcinoma or combined tumors in a cirrhotic liver is considered a contraindication for transplantation. Our aim was to evaluate the long-term outcomes of patients with incidental cholangiocarcinoma or combined tumors after liver transplantation. Methods: In our descriptive analysis, data were evaluated from all patients since 2010 who received a liver transplant due to an assumed hepatocellular carcinoma at Jena University Hospital. Survival rates were determined using the Kaplan–Meier method. Results: Between January 2010 and December 2022, an incidental intrahepatic cholangiocarcinoma was found in eight patients post-transplant. Four combined hepatocellular and cholangiocarcinoma and four sole intrahepatic cholangiocarcinomas were found. A recurrence through distant metastases from combined hepatocellular- and cholangiocarcinoma was found in one patient at one year after transplantation. Another patient developed a pulmonary primary tumor independently one year post-transplant. The recurrence rate was at 14.3%. While two patients died, the 1- and 5-year overall survival rates post-transplant were 87.5% and 75%, respectively. Conclusion: Patients with intrahepatic cholangiocarcinoma or combined hepatocellular- and cholangiocarcinoma could profit from liver transplantation.
Purpose: This study was designed to elucidate the various new classifications and the use of LDLT and bridging therapy for HCC in this context beyond the Milan criteria (MC). Methods: The clinical data of patients with HCC outside the MC who underwent LT at Jena University between January 2007 and August 2023 were retrospectively analysed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall and disease-free survival rates were compared between LT and LDLT within the context of bridging therapy. The Results: Among the 245 patients analysed, 120 patients did not meet the MC, and 125 patients met the MC. Moreover, there were comparable overall survival rates between patients outside the MC for LT versus LDLT (OS 44.3 months vs. 28.3 months; 5-year survival, 56.4% vs. 40%; p = 0.84). G3 tumour differentiation, the presence of angioinvasion and lack of bridging were statistically significant risk factors for tumour recurrence according to univariate and multivariate analyses (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provided a significant survival advantage regardless of the transplant procedure (OS: p = 0.008; DFS: p < 0.001). Conclusions: Patients with HCC outside the MC who underwent LT or LDLT had worse outcomes compared to those of patients who met the MC but still had a survival advantage compared to patients without transplantation. Nevertheless, such patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients because of differences in tumour differentiation, size and tumour marker dynamics.
Background: Pilonidal sinus disease (PSD) is a frequently occurring condition that can have a significant impact on quality of life (QoL). In addition to severe pain, particularly with movement or while sitting, this disease imposes restrictions that affect one’s professional and private life. These patients frequently suffer from recurrence requiring multiple interventions and hospital stays. Methods: The study enrolled forty-seven patients who presented with PSD from August 2010 until June 2019 and underwent primary excision and LP at the Department of General, Visceral, and Vascular Surgery at University Hospital, Jena. Forty- one of these patients were questioned retrospectively in writing or by telephone interviews between July 2021 to September 2022. The data processed using SPSS software. Results: The median follow-up for all patients was 86 months (range, 23–140 months). Only one recurrence (2.4%) was reported. While the participants’ BMIs remained unchanged, they reported significant improvements in QoL, notably in five of the six activities of daily living that were evaluated. Conclusion: The low rate of recurrence suggests that LP is an effective option for post-excision surgical repair of pilonidal sinus. The use of this procedure has no impact on patient’s BMI but can significantly improve patients’ QoL.
Liver transplantation may be a curative treatment option in patients with otherwise unresectable liver metastases. We sought to evaluate the long-term outcomes of transplantation candidates by comparing 2 groups: one treated with living-donor liver transplantation and the other, due to the absence of available living donors, receiving the current gold standard of chemotherapy only. Eligibility for inclusion of patients with unresectable liver metastases required either stable disease or tumor regression after systemic chemotherapy with no extrahepatic tumor burden. Patients were divided into 2 cohorts according to the availability of a suitable living donor. The fundamental technical principle is a 2-stage transplantation procedure, also referred to as the RAPID technique (Resection and Partial Liver Transplantation with Delayed Hepatectomy). In the first operation, a left hemihepatectomy is carried out in the recipient, followed by orthotopic transplantation of the left lateral liver lobe (segments II and III) from a living donor. To promote graft hypertrophy, portal vein ligation is undertaken. In the second step of the operation, the remaining right lobe of the liver will be removed. The 3-year and 5-year survival rates for the transplantation group were 71.3% and 57%, respectively, compared with 33.3% and 11.1%, respectively, for 15 patients with a negative donor evaluation. The recurrence rate among transplanted patients was 58%. The median disease-free survival time between liver transplantation and recurrence or death was 17.4 months. For those who experienced a recurrence, the median survival time from recurrence was 25.6 months. Liver transplantation for patients with unresectable colorectal liver metastases leads to a significant survival advantage compared with chemotherapy alone. Living-donor liver transplantation is a suitable and safe method to expand organ availability for selected patients.
22 April 2026 in Zeitschrift für Gastroenterologie
Living donor liver transplantation (LDLT) represents an important alternative to deceased donor transplantation, particularly in times of organ shortage. This study analyzes the selection process of living liver donors at a German transplant center that performs both living and deceased donor liver transplantations. In a retrospective analysis, potential living liver donors were evaluated. Medical data and reasons for donor exclusion were collected, and recipient cohorts were categorized according to transplantation indication and urgency. Donor outcomes were also assessed. Between January 2013 and December 2023, a total of 594 potential living donors were evaluated at Jena University Hospital. Of these, 124 successfully proceeded to donation. During the outpatient evaluation phase, 357 donors were excluded. Subsequently, 237 individuals underwent inpatient assessments, of whom an additional 100 were excluded. The main reasons for donor exclusion were medical or psychological contraindications (n = 160), as well as donor-independent factors such as disease progression in the recipient (n = 90) or withdrawal of consent by either the recipient or the donor (n = 54). Particularly among recipients with malignant diseases who had little or no chance of receiving a deceased donor organ, a high willingness to donate was observed—even among distant relatives or unrelated donors. A standardized evaluation protocol improves the efficiency of living donor liver transplantation within the Eurotransplant region and ensures donor safety. Diverse contraindications necessitate targeted exclusion diagnostics for individual potential donors.